<p>加拿大邮政公司注册养老金计划在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 13.8%，根据该公司最近向证券交易委员会提交的 13F 文件。该公司在此期间额外购买了 47,286 股后，持有辉瑞公司 390,128 股股票。加拿大邮政公司注册养老金计划在辉瑞的持股在最近的报告期末价值为 9,714,000 美元。</p>
<ul>
<li>应对大型制药专利悬崖的两种方式</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度将其在辉瑞的持股增加了 1,282.4%。Brighton Jones LLC 现在拥有辉瑞公司 666,318 股股票，价值 17,677,000 美元，此前在上个季度额外购买了 618,117 股。Revolve Wealth Partners LLC 在第四季度将其在辉瑞的持股增加了 12.5%。Revolve Wealth Partners LLC 现在拥有辉瑞公司 18,766 股股票，价值 498,000 美元，此前在上个季度额外购买了 2,087 股。United Bank 在第二季度将其在辉瑞的持股增加了 12.4%。United Bank 现在拥有辉瑞公司 58,087 股股票，价值 1,408,000 美元，此前在上个季度额外购买了 6,415 股。Sei Investments Co.在第二季度将其在辉瑞的持股增加了 31.5%。Sei Investments Co.现在拥有辉瑞公司 2,635,691 股股票，价值 63,889,000 美元，此前在此期间额外购买了 631,523 股。最后，HUB Investment Partners LLC 在第二季度将其在辉瑞的持股增加了 45.3%。HUB Investment Partners LLC 现在拥有辉瑞公司 102,327 股股票，价值 2,480,000 美元，此前在上个季度额外购买了 31,896 股。68.36% 的股票由机构投资者和对冲基金持有。</p>
<h2>辉瑞公司关键新闻</h2>
<p>以下是本周影响辉瑞公司的关键新闻：</p>
<ul>
<li>积极情绪：辉瑞宣布其血友病疗法 Hympavzi 在欧洲的标签扩展，这可能扩大该药物的商业机会并支持长期收入增长。</li>
<li>积极情绪：多个更新突显了持续的临床和开发活动，包括针对 Nurtec ODT 的新韩国偏头痛研究、PF-07799933 的第一阶段食物效应研究、一个 prazosin 场地转移试验，以及计划中的日本 RSV 疫苗试验。这些都加强了辉瑞的产品线和全球扩展努力。</li>
<li>积极情绪：关于辉瑞第一季度收益的近期评论指出，新产品和收购产品的势头正在改善，尤其是在肿瘤学和偏头痛治疗方面，以及 Seagen 整合和法律和解的进展可能改善未来现金流的清晰度。</li>
<li>中性情绪：媒体报道还指出，投资者情绪仍然混合，一些分析师和评论员认为辉瑞仍然缺乏强劲的收益势头，更多依赖于其股息和防御性估值，而不是明确的短期增长催化剂。</li>
<li>消极情绪：辉瑞继续面临关于 COVID 相关销售下降和即将到来的专利到期的担忧，这些因素在收益超出预期后仍对股价造成压力。</li>
</ul>
<h2>辉瑞股票下跌 1.7%</h2>
<ul>
<li>5 只高收益股票为您的投资组合抵御风暴</li>
</ul>
<p>辉瑞股票周五开盘价为 25.31 美元。辉瑞公司一年的最低价为 22.45 美元，最高价为 28.75 美元。该公司的市值为 1,442.5 亿美元，市盈率为 19.32，贝塔值为 0.35。该公司的流动比率为 1.25，速动比率为 0.94，债务与股本比率为 0.67。该股票的 50 日移动平均价格为 26.98 美元，200 日移动平均价格为 26.19 美元。</p>
<p>辉瑞（NYSE:PFE - 获取免费报告）最近于 5 月 5 日星期二发布了其收益结果。这家生物制药公司报告该季度每股收益为 0.75 美元，超出市场共识预期的 0.72 美元，超出 0.03 美元。该公司该季度的收入为 144.5 亿美元，而分析师预期为 138.4 亿美元。辉瑞的股本回报率为 19.44%，净利润率为 11.83%。该公司的季度收入同比增长 5.4%。在去年同期，该公司每股收益为 0.92 美元。辉瑞已将其 2026 财年的指导目标设定为 2.800-3.000 每股收益。作为一个整体，分析师预计辉瑞公司在当前财年将发布 2.99 每股收益。</p>
<h2>辉瑞宣布分红</h2>
<ul>
<li>辉瑞因第四季度业绩上涨——但这可能是最重要的催化剂</li>
</ul>
<p>该公司还最近披露了一项季度分红，将于 6 月 12 日星期五支付。5 月 8 日星期五的登记股东将获得 0.43 美元的分红。这代表着每年 1.72 美元的分红，收益率为 6.8%。除息日期为 5 月 8 日星期五。辉瑞的分红支付比率目前为 131.30%。</p>
<h2>分析师评级变动</h2>
<p>几家券商最近对辉瑞（PFE）发表了评论。巴克莱在 2 月 19 日（星期四）的一份报告中开始覆盖辉瑞，给予 “减持” 评级，并设定 25.00 美元的目标价。美国银行在 4 月 9 日（星期四）的一份研究报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并给予该公司 “中性” 评级。阿古斯在 3 月 2 日（星期一）的一份研究报告中将辉瑞的股票评级从 “持有” 上调至 “买入”，并设定 35.00 美元的目标价。加拿大皇家银行在 4 月 20 日（星期一）重新发布了 “表现不佳” 评级，并对辉瑞的股票设定 25.00 美元的目标价。最后，古根海姆在 3 月 24 日（星期二）的一份研究报告中将辉瑞的目标价从 35.00 美元上调至 36.00 美元，并给予该公司 “买入” 评级。一位分析师对该股票给予了强烈买入评级，六位分析师给予了买入评级，十二位分析师给予了持有评级，三位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “持有”，共识目标价为 28.84 美元。</p>
<p><strong>查看我们对辉瑞的最新股票分析</strong></p>
<h2>关于辉瑞</h2>
<p>（免费报告）</p>
<p>辉瑞公司（NYSE: PFE）是一家总部位于纽约市的跨国生物制药公司。公司由查尔斯·辉瑞和查尔斯·厄哈特于 1849 年创立，专注于人类健康的广泛药物和疫苗的研究、开发、生产和商业化。其活动涵盖发现研究、临床开发、监管事务、制造和全球商业分销，涉及多个治疗领域。</p>
<p>辉瑞的产品组合和研发管道涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及相当可观的疫苗业务。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们认为比辉瑞更好的股票</li>
<li>如果油价持续上涨，值得拥有的三只股票</li>
<li>分析师青睐的三家关键航空航天组件制造商</li>
<li>谷歌的 Googlebook 将 Gemini AI 带入 PC 硬件</li>
<li>Peloton 股票在乐观的财报后回吐涨幅</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

辉瑞

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>加拿大邮政公司注册养老金计划在第四季度将其在辉瑞公司（NYSE:PFE）的持股增加了 13.8%，目前持有 390,128 股，价值 970 万美元。其他机构投资者也提高了他们的持仓。尽管辉瑞的产品线有积极进展，但对 COVID 销售下滑和专利到期的担忧依然存在，股价下跌了 1.7%。辉瑞报告第一季度每股收益为 0.75 美元，超出预期，并将 2026 财年的指导目标设定在每股收益 2.800-3.000 美元</p>

<p>Canada Post Corp Registered Pension Plan increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 390,128 shares of the biopharmaceutical company's stock after acquiring an additional 47,286 shares during the period. Canada Post Corp Registered Pension Plan's holdings in Pfizer were worth $9,714,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>加拿大邮政公司注册养老金计划在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股增加了 13.8%，根据该公司最近向证券交易委员会提交的 13F 文件。该公司在此期间额外购买了 47,286 股后，持有辉瑞公司 390,128 股股票。加拿大邮政公司注册养老金计划在辉瑞的持股在最近的报告期末价值为 9,714,000 美元。</p>
</div><ul>
<li>2 Ways to Play the Big Pharma Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>应对大型制药专利悬崖的两种方式</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank raised its stake in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. lifted its holdings in Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock worth $63,889,000 after purchasing an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC grew its position in Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock valued at $2,480,000 after buying an additional 31,896 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度将其在辉瑞的持股增加了 1,282.4%。Brighton Jones LLC 现在拥有辉瑞公司 666,318 股股票，价值 17,677,000 美元，此前在上个季度额外购买了 618,117 股。Revolve Wealth Partners LLC 在第四季度将其在辉瑞的持股增加了 12.5%。Revolve Wealth Partners LLC 现在拥有辉瑞公司 18,766 股股票，价值 498,000 美元，此前在上个季度额外购买了 2,087 股。United Bank 在第二季度将其在辉瑞的持股增加了 12.4%。United Bank 现在拥有辉瑞公司 58,087 股股票，价值 1,408,000 美元，此前在上个季度额外购买了 6,415 股。Sei Investments Co.在第二季度将其在辉瑞的持股增加了 31.5%。Sei Investments Co.现在拥有辉瑞公司 2,635,691 股股票，价值 63,889,000 美元，此前在此期间额外购买了 631,523 股。最后，HUB Investment Partners LLC 在第二季度将其在辉瑞的持股增加了 45.3%。HUB Investment Partners LLC 现在拥有辉瑞公司 102,327 股股票，价值 2,480,000 美元，此前在上个季度额外购买了 31,896 股。68.36% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Key Pfizer News</h2>
<div class="lb-trans"><h2>辉瑞公司关键新闻</h2>
</div><p>Here are the key news stories impacting Pfizer this week:</p>
<div class="lb-trans"><p>以下是本周影响辉瑞公司的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.</li>
<li>Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.</li>
<li>Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.</li>
<li>Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.</li>
<li>Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：辉瑞宣布其血友病疗法 Hympavzi 在欧洲的标签扩展，这可能扩大该药物的商业机会并支持长期收入增长。</li>
<li>积极情绪：多个更新突显了持续的临床和开发活动，包括针对 Nurtec ODT 的新韩国偏头痛研究、PF-07799933 的第一阶段食物效应研究、一个 prazosin 场地转移试验，以及计划中的日本 RSV 疫苗试验。这些都加强了辉瑞的产品线和全球扩展努力。</li>
<li>积极情绪：关于辉瑞第一季度收益的近期评论指出，新产品和收购产品的势头正在改善，尤其是在肿瘤学和偏头痛治疗方面，以及 Seagen 整合和法律和解的进展可能改善未来现金流的清晰度。</li>
<li>中性情绪：媒体报道还指出，投资者情绪仍然混合，一些分析师和评论员认为辉瑞仍然缺乏强劲的收益势头，更多依赖于其股息和防御性估值，而不是明确的短期增长催化剂。</li>
<li>消极情绪：辉瑞继续面临关于 COVID 相关销售下降和即将到来的专利到期的担忧，这些因素在收益超出预期后仍对股价造成压力。</li>
</ul>
</div><h2>Pfizer Stock Down 1.7%</h2>
<div class="lb-trans"><h2>辉瑞股票下跌 1.7%</h2>
</div><ul>
<li>5 High-Yield Stocks to Shield Your Portfolio From the Storm</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只高收益股票为您的投资组合抵御风暴</li>
</ul>
</div><p>Shares of Pfizer stock opened at $25.31 on Friday. Pfizer Inc. has a 1 year low of $22.45 and a 1 year high of $28.75. The company has a market cap of $144.25 billion, a P/E ratio of 19.32 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock has a 50-day moving average price of $26.98 and a 200 day moving average price of $26.19.</p>
<div class="lb-trans"><p>辉瑞股票周五开盘价为 25.31 美元。辉瑞公司一年的最低价为 22.45 美元，最高价为 28.75 美元。该公司的市值为 1,442.5 亿美元，市盈率为 19.32，贝塔值为 0.35。该公司的流动比率为 1.25，速动比率为 0.94，债务与股本比率为 0.67。该股票的 50 日移动平均价格为 26.98 美元，200 日移动平均价格为 26.19 美元。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最近于 5 月 5 日星期二发布了其收益结果。这家生物制药公司报告该季度每股收益为 0.75 美元，超出市场共识预期的 0.72 美元，超出 0.03 美元。该公司该季度的收入为 144.5 亿美元，而分析师预期为 138.4 亿美元。辉瑞的股本回报率为 19.44%，净利润率为 11.83%。该公司的季度收入同比增长 5.4%。在去年同期，该公司每股收益为 0.92 美元。辉瑞已将其 2026 财年的指导目标设定为 2.800-3.000 每股收益。作为一个整体，分析师预计辉瑞公司在当前财年将发布 2.99 每股收益。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>辉瑞宣布分红</h2>
</div><ul>
<li>Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞因第四季度业绩上涨——但这可能是最重要的催化剂</li>
</ul>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date is Friday, May 8th. Pfizer's dividend payout ratio is currently 131.30%.</p>
<div class="lb-trans"><p>该公司还最近披露了一项季度分红，将于 6 月 12 日星期五支付。5 月 8 日星期五的登记股东将获得 0.43 美元的分红。这代表着每年 1.72 美元的分红，收益率为 6.8%。除息日期为 5 月 8 日星期五。辉瑞的分红支付比率目前为 131.30%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several brokerages recently commented on PFE. Barclays began coverage on Pfizer in a report on Thursday, February 19th. They set an &#34;underweight&#34; rating and a $25.00 target price on the stock. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, April 9th. Argus upgraded shares of Pfizer from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. Royal Bank Of Canada reissued an &#34;underperform&#34; rating and issued a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. Finally, Guggenheim raised their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and a consensus price target of $28.84.</p>
<div class="lb-trans"><p>几家券商最近对辉瑞（PFE）发表了评论。巴克莱在 2 月 19 日（星期四）的一份报告中开始覆盖辉瑞，给予 “减持” 评级，并设定 25.00 美元的目标价。美国银行在 4 月 9 日（星期四）的一份研究报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并给予该公司 “中性” 评级。阿古斯在 3 月 2 日（星期一）的一份研究报告中将辉瑞的股票评级从 “持有” 上调至 “买入”，并设定 35.00 美元的目标价。加拿大皇家银行在 4 月 20 日（星期一）重新发布了 “表现不佳” 评级，并对辉瑞的股票设定 25.00 美元的目标价。最后，古根海姆在 3 月 24 日（星期二）的一份研究报告中将辉瑞的目标价从 35.00 美元上调至 36.00 美元，并给予该公司 “买入” 评级。一位分析师对该股票给予了强烈买入评级，六位分析师给予了买入评级，十二位分析师给予了持有评级，三位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票的共识评级为 “持有”，共识目标价为 28.84 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Pfizer</strong></p>
<div class="lb-trans"><p><strong>查看我们对辉瑞的最新股票分析</strong></p>
</div><h2>About Pfizer</h2>
<div class="lb-trans"><h2>关于辉瑞</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>辉瑞公司（NYSE: PFE）是一家总部位于纽约市的跨国生物制药公司。公司由查尔斯·辉瑞和查尔斯·厄哈特于 1849 年创立，专注于人类健康的广泛药物和疫苗的研究、开发、生产和商业化。其活动涵盖发现研究、临床开发、监管事务、制造和全球商业分销，涉及多个治疗领域。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>辉瑞的产品组合和研发管道涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及相当可观的疫苗业务。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>3 Stocks to Own If Gas Prices Keep Rising</li>
<li>3 Crucial Aerospace Component Makers That Analysts Love</li>
<li>Alphabet's Googlebook Brings Gemini AI to PC Hardware</li>
<li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比辉瑞更好的股票</li>
<li>如果油价持续上涨，值得拥有的三只股票</li>
<li>分析师青睐的三家关键航空航天组件制造商</li>
<li>谷歌的 Googlebook 将 Gemini AI 带入 PC 硬件</li>
<li>Peloton 股票在乐观的财报后回吐涨幅</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pfizer Inc. $PFE Stock Holdings Boosted by Canada Post Corp Registered Pension Plan

- 加拿大邮政注册养老计划在第四季度持有辉瑞公司股票增加了 13.8%。
- 辉瑞股票的市场估值为 1474.5 亿美元，季度收入为 144.5 亿美元。
- 投资者对辉瑞的情绪复杂，面临 COVID 销售下降和专利到期的担忧。

Market Beat

基因改革 ETF - ARK

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

标普全球医疗股指数 ETF - iShares

Invesco Nasdaq Biotechnology ETF

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

联合银行

SEI投资

辉瑞公司 $PFE 的股票持仓被加拿大邮政公司注册养老金计划增加